TGFB1 and renal fibrosis: Our study found that hEPO-MPs contribute toward the inhibition of TGF-β1-induced EMT in MDCK cells in vitro and improve renal fibrosis in obstructed kidneys in vivo in a similar manner to that of rhEPO; thus, they may be used as a novel therapeutic agent.